JPRN-UMIN000021585
Completed
Phase 2
A phase II study of eribulin in combination with trastuzumab and pertuzumab as First-Line therapy for metastatic HER2-positive breast cancer - SBCCSG-36
Sairtama Breast Cancer Clinical Study Group (SBCCSG)0 sites16 target enrollmentMarch 23, 2016
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- First-Line therapy for metastatic HER2-positive breast cancer.
- Sponsor
- Sairtama Breast Cancer Clinical Study Group (SBCCSG)
- Enrollment
- 16
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\.Active infection or fever at risk of infection 2\.History of serious drug allergies 3\.Spontanous serious renal damage or liver dysfunction(jaundice) 4\.Large pleural effusion or ascites requiring repeat drainage 5\.Systemic administration of steroid drug 6\.Pregnant females or females of child\-bearing potential 7\.Concurrent active other malignancy 8\.Metachronous or spontaneous bilateral breast cancer except ductal carcinoma in situ 9\.Clinically important mental disorder or history of central nervous system damage 10\.Clinically significant central nervous system metastases 11\.Concurrent enrollment of other clinical trial 12\.Reccurence in conserving breast or local recurrence that is appropriate therapy to reoperate 13\.HBs antigen positive 14\.Not suitable for participation with any other reasons (including rapid progression disease, life threatening status if not successfully treated)
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 2
Phase II study of the combination of Eribulin and Trastuzumab Evaluating Efficacy and Safety in Patients with advanced/recurrent HER2-positive breast cancer.Advanced/recurrent HER2-positive breast cancerJPRN-UMIN000011020Sairtama Breast Cancer Clinical Study Group (SBCCSG)na35
Active, not recruiting
Phase 1
A Phase II study of a Combination of Eribulin and capecitabiNe in second line Treatment after the failure of gemcitabine/abraxane first line in advanced pancreatic canceradvanced pancreatic cancerMedDRA version: 21.0Level: LLTClassification code 10033599Term: Pancreatic adenocarcinoma metastaticSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2017-003621-15-ITAZIENDA OSPEDALIERO-UNIVERSITARIA DI MODENA25
Completed
Phase 2
A phase 2 study of eribulin in combination with pertuzumab and trastuzumab for advanced or recurrent human epidermal growth factor receptor 2 (HER2)-positive breast cancerJPRN-UMIN000014107SONG (South Osaka Network Group for Breast Cancer)43
Completed
Not Applicable
A Phase II Study of Eribulin Evaluating Efficacy and Safety as first or secondary line chemotherapy for advanced or metastatic breast cancer without HER2 overexpressingAdvanced or metastatic breast cancerJPRN-UMIN000009568General and Gastroenterological Surgery, Osaka Medical College35
Recruiting
Not Applicable
Exploratory clinical study of eribulin followed by taxane for metastatic breast cancer patientsMetastatic breast cancerJPRN-UMIN000027527Yamaguchi University Graduate School of Medicine30